0
0
The National Immunization Panel (NIG) last night released updated recommendations for use of the CoV vaccine. In it, the panel writes that in light of the Omicron variant, the rate of third vaccinations should be “increased as soon as possible.” To have a lasting impact on the pandemic, reducing viral circulation by maximizing vaccination coverage must be the long-term goal, it said.
Due to a lack of scientific data, the fourth vaccination is not generally recommended at this time, he said. “However, given the threat of an omicron wave, it may be offered in high-risk areas (e.g., exposed health care workers) and in system-critical areas starting 6 months after the 3rd vaccination,” it said. However, this should only take place after individual medical assessment and at the request of the person to be vaccinated (“off label”). There is no evidence yet that this additional vaccination can prevent infections, it said. “However, it can be expected to prevent serious illness,” the NIG said.
Novavax’s vaccine, which was recently approved by the EU, was also added to the list of vaccines. First shipments to Austria are expected in the first Q1 of 2022, it said. Currently, the vaccine should be used primarily for first-time vaccinations and individuals with contraindications to previously approved vaccines, it said.
In its recommendations, the NIG explicitly warned against the Omicron variant. Therefore, it said, vaccinating individuals “should be approached with a high degree of flexibility.” Those willing to be vaccinated should not be turned away at the vaccination appointment, “even if in individual cases recommended vaccination intervals cannot be adhered to by a few days.” Vaccination should only not be carried out if there are explicit contraindications.
- source: orf.at/picture: Image by fernando zhiminaicela from Pixabay
This post has already been read 510 times!
